Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes

Epigenomics

Volumn 6, Issue 4, 2014, Pages 381-395

  Li, Wangzhi ^a,b   Mills, Alea A ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

cancer; CHD proteins; chromatin remodeling; copy number variation; developmental disorders; DNA damage; male infertility; mutation; neurological syndromes

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING PROTEIN; DNA HELICASE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN;

CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMODOMAIN HELICASE DNA BINDING DYSFUNCTION; DEREGULATION; DEVELOPMENTAL DISORDER; DNA BINDING; DNA DAMAGE; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; NEOPLASM; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SYNDROME CHARGE; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; GENOME;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEVELOPMENTAL DISABILITIES; DNA HELICASES; DNA-BINDING PROTEINS; GENOME; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 84908209938     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.31     Document Type: Review

References (149)

1. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78, 273-304 (2009).
2. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling. Trends Mol. Med. 13(9), 373-380 (2007).
3. Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat. Res. 618(1-2), 30-40 (2007).
4. Hall JA, Georgel PT. CHD proteins: a diverse family with strong ties. Biochem. Cell. Biol. 85(4), 463-476 (2007).
5. Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. Characterization of the CHD family of proteins. Proc. Natl Acad. Sci. USA 94(21), 11472-11477 (1997).
6. Delmas V, Stokes DG, Perry RP. A mammalian DNAbinding protein that contains a chromodomain and an SNF2/SWI2-like helicase domain. Proc. Natl Acad. Sci. USA 90(6), 2414-2418 (1993).
7. Watson AA, Mahajan P, Mertens HD et al. The PHD and chromo domains regulate the ATPase activity of the human chromatin remodeler CHD4. J. Mol. Biol 422(1), 3-17 (2012).
8. Bouazoune K, Kingston RE. Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders. Proc. Natl Acad. Sci. USA 109(47), 19238-19243 (2012).
9. Thompson BA, Tremblay V, Lin G, Bochar DA. CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes. Mol. Cell. Biol. 28(12), 3894-3904 (2008).
10. Lutz T, Stoger R, Nieto A. CHD6 is a DNA-dependent ATPase and localizes at nuclear sites of mRNA synthesis. FEBS Lett. 580(25), 5851-5857 (2006).
11. Lusser A, Urwin DL, Kadonaga JT. Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. Nat. Struct. Mol. Biol. 12(2), 160-166 (2005).
12. Eissenberg JC. Structural biology of the chromodomain: form and function. Gene 496(2), 69-78 (2012).
13. Bouazoune K, Mitterweger A, Langst G et al. The dMi-2 chromodomains are DNA binding modules important for ATP-dependent nucleosome mobilization. EMBO J. 21(10), 2430-2440 (2002).
14. Ramirez J, Dege C, Kutateladze TG, Hagman J. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol. Cell. Biol. 32(24), 5078-5088 (2012).
15. Flanagan JF, Mi LZ, Chruszcz M et al. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 438(7071), 1181-1185 (2005).
16. Egan CM, Nyman U, Skotte J et al. CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev. Cell. 26(3), 223-236 (2013).
17. Musselman CA, Kutateladze TG. Handpicking epigenetic marks with PHD fingers. Nucleic Acids Res. 39(21), 9061-9071 (2011).
18. Sanchez R, Zhou MM. The PHD finger: a versatile epigenome reader. Trends Biochem. Sci. 36(7), 364-372 (2011).
19. Mansfield RE, Musselman CA, Kwan AH et al. Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. J. Biol. Chem. 286(13), 11779-11791 (2011).
20. Musselman CA, Mansfield RE, Garske AL et al. Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem. J. 423(2), 179-187 (2009).
21. Musselman CA, Ramirez J, Sims JK et al. Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4 ATPase is required for CHD4-mediated repression. Proc. Natl Acad. Sci. USA 109(3), 787-792 (2012).
22. Paul S, Kuo A, Schalch T et al. Chd5 requires PHDmediated histone 3 binding for tumor suppression. Cell Rep. 3(1), 92-102 (2013).
23. Ooi SKT, Qiu C, Bernstein E et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448(7154), 714-717 (2007).
24. Li HT, Ilin S, Wang WK et al. Molecular basis for sitespecific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442(7098), 91-95 (2006).
25. Pena PV, Davrazou F, Shi XB et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442(7098), 100-103 (2006).
26. Wysocka J, Swigut T, Xiao H et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442(7098), 86-90 (2006).
27. Lan F, Collins RE, De Cegli R et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 448(7154), 718-722 (2007).
28. Boyer LA, Latek RR, Peterson CL. The SANT domain: a unique histone-tail-binding module? Nat. Rev. Mol. Cell Biol. 5(2), 158-163 (2004).
29. Urquhart AJ, Gatei M, Richard DJ, Khanna KK. ATM mediated phosphorylation of CHD4 contributes to genome maintenance. Genome Integr. 2(1), 1 (2011).
30. Oshaughnessy A, Hendrich B. CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now. Biochem. Soc. Trans. 41(3), 777-782 (2013).
31. Larsen DH, Poinsignon C, Gudjonsson T et al. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. J. Cell Biol. 190(5), 731-740 (2010).
32. Pan MR, Hsieh HJ, Dai H et al. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J. Biol. Chem. 287(9), 6764-6772 (2012).
33. Goodarzi AA, Kurka T, Jeggo PA. KAP-1 phosphorylation regulates CHD3 nucleosome remodeling during the DNA double-strand break response. Nat. Struct. Mol. Biol. 18(7), 831-839 (2011).
34. Rajagopalan S, Nepa J, Venkatachalam S. Chromodomain helicase DNA-binding protein 2 affects the repair of X-ray and UV-induced DNA damage. Environ. Mol. Mutagen. 53(1), 44-50 (2012).
35. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S. Role of chromodomain helicase DNAbinding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 28(8), 1053-1062 (2009).
36. Ling T, Xie W, Luo M et al. CHD4/NuRD maintains demethylation state of rDNA promoters through inhibiting the expression of the rDNA methyltransferase recruiter TIP5. Biochem. Biophys. Res. Commun. 437(1), 101-107 (2013).
37. Zentner GE, Hurd EA, Schnetz MP et al. CHD7 functions in the nucleolus as a positive regulator of ribosomal RNA biogenesis. Hum. Mol. Genet. 19(18), 3491-3501 (2010).
38. Yuan CC, Zhao X, Florens L, Swanson SK, Washburn MP, Hernandez N. CHD8 associates with human Staf and contributes to efficient U6 RNA polymerase III transcription. Mol. Cell. Biol. 27(24), 8729-8738 (2007).
39. Stanley FK, Moore S, Goodarzi AA. CHD chromatin remodelling enzymes and the DNA damage response. Mutat. Res. 750(1-2), 31-44 (2013).
40. Bagchi A, Papazoglu C, Wu Y et al. CHD5 is a tumor suppressor at human 1p36. Cell 128(3), 459-475 (2007).
41. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 68(8), 2551-2556 (2008).
42. Oliver SS, Musselman CA, Srinivasan R, Svaren JP, Kutateladze TG, Denu JM. Multivalent recognition of histone tails by the PHD fingers of CHD5. Biochemistry 51(33), 6534-6544 (2012).
43. Fujita T, Igarashi J, Okawa ER et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl Cancer Inst. 100(13), 940-949 (2008).
44. Garcia I, Mayol G, Rodriguez E et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 9, 277 (2010).
45. Li H, Xu W, Huang Y, Huang X, Xu L, Lv Z. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. Int. J. Mol. Med. 30(5), 1081-1086 (2012).
46. Koyama H, Zhuang T, Light JE et al. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin. Cancer Res. 18(6), 1588-1597 (2012).
47. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22(7), 1002-1011 (2003).
48. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3(4), 210-215 (2008).
49. Wang L, He S, Tu Y et al. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma. J. Clin. Neurosci. 20(7), 958-963 (2013).
50. Wu X, Zhu Z, Li W et al. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res. 14(3), R73 (2012).
51. Zhao R, Yan Q, Lv J et al. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 76(3), 324-331 (2012).
52. Wong RR, Chan LK, Tsang TP et al. CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol. Obstet. Invest. 72(3), 203-207 (2011).
53. Wang X, Lau KK, So LK, Lam YW. CHD5 is downregulated through promoter hypermethylation in gastric cancer. J. Biomed. Sci. 16, 95 (2009).
54. Du X, Wu T, Lu J et al. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma. Clin. Transl. Oncol. 15(3), 198-204 (2013).
55. Cai C, Ashktorab H, Pang X et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PloS One 7(1), e29750 (2012).
56. Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H, Ashktorab H. Epigenetic silencing of CHD5, a novel tumorsuppressor gene, occurs in early colorectal cancer stages. Cancer 120(2), 172-180 (2014).
57. Zhao R, Wang N, Huang H, Ma W, Yan Q. CHD5, a tumor suppressor is epigenetically silenced in hepatocellular carcinoma. Liver Int. 34(6), e151-160 (2014).
58. Lang J, Tobias ES, Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br. J. Dermatol. 164(5), 1010-1016 (2011).
59. Zhao R, Meng F, Wang N, Ma W, Yan Q. Silencing of CHD5 gene by promoter methylation in leukemia. PloS One 9(1), e85172 (2014).
60. Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol. 47(7), 601-608 (2011).
61. Egan CM, Julie Skotte, Gundula Streubel et al. CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev. Cell 26(3), 223-236 (2013).
62. Potts RC, Zhang P, Wurster AL et al. CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PloS One 6(9), e24515 (2011).
63. Vestin A, Mills AA. The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. Gene Expr. Patterns 13(8), 482-489 (2013).
64. Li W, Wu J, Kim SY et al. Chd5 orchestrates chromatin remodelling during sperm development. Nat. Commun. 5, 3812 (2014).
65. Zhuang T, Hess RA, Kolla V, Higashi M, Raabe TD, Brodeur GM. CHD5 is required for spermiogenesis and chromatin condensation. Mech. Dev. 131, 35-46 (2014).
66. Vestin A, Mills AA. The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. Gene Expr. Patterns 13(8), 482-489 (2013).
67. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 58(5), 660-668 (2011).
68. Tahara T, Yamamoto E, Madireddi P et al. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology 146(2), 530-538 e535 (2014).
69. Sawada G, Ueo H, Matsumura T et al. CHD8 is an independent prognostic indicator that regulates Wnt/betacatenin signaling and the cell cycle in gastric cancer. Oncol. Rep. 30(3), 1137-1142 (2013).
70. Rodriguez-Paredes M, Ceballos-Chavez M, Esteller M, Garcia-Dominguez M, Reyes JC. The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the cyclin E2 gene. Nucleic Acids Res. 37(8), 2449-2460 (2009).
71. Colbert LE, Petrova AV, Fisher SB et al. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Cancer Res. 74(10), 2677-2687 (2014).
72. Pleasance ED, Stephens PJ, Omeara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010).
73. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40(6), 722-729 (2008).
74. Burkhardt L, Fuchs S, Krohn A et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73(9), 2795-2805 (2013).
75. Liu W, Lindberg J, Sui G et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 31(35), 3939-3948 (2012).
76. Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31(37), 4164-4170 (2012).
77. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 470(7333), 214-220 (2011).
78. Grasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406), 239-243 (2012).
79. Le Gallo M, Ohara AJ, Rudd ML et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat. Genet. 44(12), 1310-1315 (2012).
80. Zhao S, Choi M, Overton JD et al. Landscape of somatic single-nucleotide and copy-number. Proc. Natl Acad. Sci. USA 110(8), 2916-2921 (2013).
81. Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J. 29(18), 3130-3139 (2010).
82. Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 11(8), 588-596 (2011).
83. Li R, Zhang H, Yu W et al. ZIP: a novel transcription repressor, represses EGFR oncogene and suppresses breast carcinogenesis. EMBO J. 28(18), 2763-2776 (2009).
84. Mouradov D, Sloggett C, Jorissen RN et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74(12), 3238-3247 (2014).
85. Ali Hassan NZ, Mokhtar NM, Kok Sin T et al. Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues. PloS One 9(4), e92553 (2014).
86. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43(9), 875-878 (2011).
87. Kulkarni S, Nagarajan P, Wall J et al. Disruption of chromodomain helicase DNA binding protein 2 (CHD2) causes scoliosis. Am. J. Med. Genet. A 146A(9), 1117-1127 (2008).
88. Oroak BJ, Vives L, Fu W et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338(6114), 1619-1622 (2012).
89. Neale BM, Kou Y, Liu L et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485(7397), 242-245 (2012).
90. Talkowski ME, Rosenfeld JA, Blumenthal I et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149(3), 525-537 (2012).
91. Oroak BJ, Vives L, Girirajan S et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485(7397), 246-250 (2012).
92. Mccarthy SE, Gillis J, Kramer M et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol. Psychiatry 19(6), 652-658 (2014).
93. Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, Van Ravenswaaij-Arts CM. CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J. Med. Genet. 48(5), 334-342 (2011).
94. De Arriba Munoz A, Monge Galindo L, Lopez Pison J et al. CHARGE syndrome and CHD7 gene mutation. Neurologia 26(4), 255 (2011).
95. Jongmans MC, Admiraal RJ, Van Der Donk KP et al. CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 gene. J. Med. Genet. 43(4), 306-314 (2006).
96. Wincent J, Holmberg E, Stromland K et al. CHD7 mutation spectrum in 28 Swedish patients diagnosed with CHARGE syndrome. Clin. Genet. 74(1), 31-38 (2008).
97. Martin DM. Chromatin remodeling in development and disease: focus on CHD7. PLoS Genet. 6(7), e1001010 (2010).
98. Layman WS, Hurd EA, Martin DM. Chromodomain proteins in development: lessons from CHARGE syndrome. Clin. Genet. 78(1), 11-20 (2010).
99. Johansson M, Gillberg C, Rastam M. Autism spectrum conditions in individuals with Mobius sequence, CHARGE syndrome and oculo-auriculo-vertebral spectrum: diagnostic aspects. Res. Dev. Disabil. 31(1), 9-24 (2010).
100. Vervloed MP, Hoevenaars-Van Den Boom MA, Knoors H, Van Ravenswaaij CM, Admiraal RJ. CHARGE syndrome: relations between behavioral characteristics and medical conditions. Am. J. Med. Genet. A 140(8), 851-862 (2006).
101. Hartshorne TS, Grialou TL, Parker KR. Autistic-like behavior in CHARGE syndrome. Am. J. Med. Genet. A 133A(3), 257-261 (2005).
102. Smith IM, Nichols SL, Issekutz K, Blake K. Canadian paediatric surveillance P: behavioral profiles and symptoms of autism in CHARGE syndrome: preliminary Canadian epidemiological data. Am. J. Med. Genet. A 133A(3), 248-256 (2005).
103. Patient CMDIA, Jiang YH, Yuen RK et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 93(2), 249-263 (2013).
104. Pinto D, Delaby E, Merico D et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 94(5), 677-694 (2014).
105. Capelli LP, Krepischi AC, Gurgel-Giannetti J et al. Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency. Eur. J. Med. Genet. 55(2), 132-134 (2012).
106. Carvill GL, Heavin SB, Yendle SC et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat. Genet. 45(7), 825-830 (2013).
107. Suls A, Jaehn JA, Kecskes A et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am. J. Hum. Genet. 93(5), 967-975 (2013).
108. Lund C, Brodtkorb E, Oye AM, Rosby O, Selmer KK. CHD2 mutations in Lennox-Gastaut syndrome. Epilepsy Behav. 33, 18-21 (2014).
109. Epi KC, Epilepsy Phenome/Genome P, Allen AS et al. De novo mutations in epileptic encephalopathies. Nature 501(7466), 217-221 (2013).
110. Rauch A, Wieczorek D, Graf E et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380(9854), 1674-1682 (2012).
111. Yamada K, Fukushi D, Ono T et al. Characterization of a de novo balanced t(4;20)(q33;q12) translocation in a patient with mental retardation. Am. J. Med. Genet. A 152A(12), 3057-3067 (2010).
112. Bennetts JS, Rendtorff ND, Simpson F, Tranebjaerg L, Wicking C. The coding region of TP53INP2, a gene expressed in the developing nervous system, is not altered in a family with autosomal recessive non-progressive infantile ataxia on chromosome 20q11-q13. Dev. Dyn. 236(3), 843-852 (2007).
113. Hertz JM, Sivertsen B, Silahtaroglu A et al. Early onset, non-progressive, mild cerebellar ataxia co-segregating with a familial balanced translocation t(8;20)(p22;q13). J. Med. Genet. 41(3), e25 (2004)
114. Tranebjaerg L, Teslovich TM, Jones M et al. Genomewide homozygosity mapping localizes a gene for autosomal recessive non-progressive infantile ataxia to 20q11-q13. Hum. Genet. 113(3), 293-295 (2003).
115. Lathrop MJ, Chakrabarti L, Eng J et al. Deletion of the Chd6 exon 12 affects motor coordination. Mamm. Genome 21(3-4), 130-142 (2010).
116. Hung H, Kohnken R, Svaren J. The nucleosome remodeling and deacetylase chromatin remodeling (NuRD) complex is required for peripheral nerve myelination. J. Neurosci. 32(5), 1517-1527 (2012).
117. Iourov IY, Vorsanova SG, Kurinnaia OS, Zelenova MA, Silvanovich AP, Yurov YB. Molecular karyotyping by array CGH in a Russian cohort of children with intellectual disability, autism, epilepsy and congenital anomalies. Mol. Cytogenet. 5(1), 46 (2012).
118. Kaminsky EB, Kaul V, Paschall J et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet. Med. 13(9), 777-784 (2011).
119. Janssen N, Bergman JE, Swertz MA et al. Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat. 33(8), 1149-1160 (2012).
120. Schnetz MP, Bartels CF, Shastri K et al. Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. Genome Res. 19(4), 590-601 (2009).
121. Jacobs-Mcdaniels NL, Albertson RC. Chd7 plays a critical role in controlling left-right symmetry during zebrafish somitogenesis. Dev. Dyn. 240(10), 2272-2280 (2011).
122. Hurd EA, Capers PL, Blauwkamp MN et al. Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple developing tissues. Mamm. Genome 18(2), 94-104 (2007).
123. Feng W, Khan MA, Bellvis P et al. The chromatin remodeler CHD7 regulates adult neurogenesis via activation of soxc transcription factors. Cell Stem Cell 13(1), 62-72 (2013).
124. Gao X, Gordon D, Zhang D et al. CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis. Am. J. Hum. Genet. 80(5), 957-965 (2007).
125. Marfella CG, Henninger N, Leblanc SE et al. A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype. Kidney Blood Press. Res. 31(6), 421-432 (2008).
126. Marfella CG, Ohkawa Y, Coles AH, Garlick DS, Jones SN, Imbalzano AN. Mutation of the SNF2 family member Chd2 affects mouse development and survival. J. Cell. Physiol. 209(1), 162-171 (2006).
127. Qin Y, Ji J, Du G et al. Comprehensive pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia risk. Hum. Reprod. 29(4), 860-866 (2014).
128. Sparmann A, Xie Y, Verhoeven E et al. The chromodomain helicase Chd4 is required for Polycomb-mediated inhibition of astroglial differentiation. EMBO J. 32(11), 1598-1612 (2013).
129. Williams CJ, Naito T, Arco PGD et al. The chromatin remodeler Mi-2 beta is required for CD4 expression and T cell development. Immunity 20(6), 719-733 (2004).
130. Hosokawa H, Tanaka T, Suzuki Y et al. Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell identity. Proc. Natl. Acad. Sci. USA 110(12), 4691-4696 (2013).
131. Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 134(8), 1571-1582 (2007).
132. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28(7), 796-803 (1985).
133. Nishiyama M, Nakayama K, Tsunematsu R, Tsukiyama T, Kikuchi A, Nakayama KI. Early embryonic death in mice lacking the beta-catenin-binding protein Duplin. Mol. Cell. Biol. 24(19), 8386-8394 (2004).
134. Nishiyama M, Oshikawa K, Tsukada Y et al. CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat. Cell Biol. 11(2), 172-182 (2009).
135. Sakamoto I, Kishida S, Fukui A et al. A novel betacatenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J. Biol. Chem. 275(42), 32871-32878 (2000).
136. Mcdaniel IE, Lee JM, Berger MS, Hanagami CK, Armstrong JA. Investigations of CHD1 function in transcription and development of Drosophila melanogaster. Genetics 178(1), 583-587 (2008).
137. Papantonis A, Tsatsarounos S, Vanden Broeck J, Lecanidou R. CHD1 assumes a central role during follicle development. J. Mol. Biol. 383(5), 957-969 (2008).
138. Gaspar-Maia A, Alajem A, Polesso F et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460(7257), 863-868 (2009).
139. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J. Autism Dev. Disord. 31(6), 569-576 (2001).
140. Kao HT, Buka SL, Kelsey KT, Gruber DF, Porton B. The correlation between rates of cancer and autism: an exploratory ecological investigation. PLoS One 5(2), e9372 (2010).
141. Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz LI. Increased risk of cancer among azoospermic men. Fertil. Steril. 100(3), 681-685 (2013).
142. Peng X, Zeng X, Peng S, Deng D, Zhang J. The association risk of male subfertility and testicular cancer: a systematic review. PloS One 4(5), e5591 (2009).
143. Mallette FA, Richard S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep. 2(5), 1233-1243 (2012).
144. Macdonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell. 17(1), 9-26 (2009).
145. Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimers Disease. Mol. Neurodegener. 3, 9 (2008).
146. De Ferrari GV, Moon RT. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25(57), 7545-7553 (2006).
147. Ronan JL, Wu W, Crabtree GR. From neural development to cognition: unexpected roles for chromatin. Nat. Rev. Genet. 14(5), 347-359 (2013).
148. Harada A, Okada S, Konno D et al. Chd2 interacts with H3.3 to determine myogenic cell fate. EMBO J. 31(13), 2994-3007 (2012).
149. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J. Biol. Chem. 281(22), 15129-15137 (2006).